New drug trial aims to help patients with rare, treatment-resistant blood disease
NCT ID NCT04854889
Summary
This study tested whether a low-dose drug called decitabine could help patients with severe aplastic anemia who didn't improve with standard treatments. The trial aimed to see if the drug could boost blood cell counts and reduce the need for blood transfusions. Only three patients were enrolled before the study was stopped early.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY APLASTIC ANEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Regenerative Medicine Center
Tianjin, Tianjin Municipality, China
Conditions
Explore the condition pages connected to this study.